dacarbazine has been researched along with Benign Neoplasms in 181 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 41 (22.65) | 18.7374 |
| 1990's | 23 (12.71) | 18.2507 |
| 2000's | 43 (23.76) | 29.6817 |
| 2010's | 69 (38.12) | 24.3611 |
| 2020's | 5 (2.76) | 2.80 |
| Authors | Studies |
|---|---|
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| Burrows, SR; Doolan, DL; Meehan, MT; Miles, JJ; Wong, Y | 1 |
| Bahadoram, M; Bahadoram, S; Hassanzadeh, S; Keikha, A; Keikhaei, B; Mahmoudian-Sani, MR | 1 |
| Badgett, T; Crimella, J; Fridley, BL; Gill, J; Gorlick, R; Llosa, N; Metts, JL; Reed, D; Sandler, E; Sansil, S; Smith, T; Thapa, R; Thompson, P; Trucco, M; Weiser, DA | 1 |
| Chen, H; Ding, Y; Hou, T; Hu, PH; Huang, MS; Li, J; Li, W; Luo, ZJ; Shen, ZT; Shu, C; Wang, B; Wang, FM; Xia, XH; Yuan, S; Zhang, S; Zhao, YH | 1 |
| Fioretzaki, R; Kosmas, C; Papageorgiou, G; Tsakatikas, S | 1 |
| Allison, SJ; Baronou, E; Cooper, PA; Dunnill, C; Georgopoulos, NT; Latif, A; Phillips, RM; Sadiq, M; Shepherd, S; Shnyder, SD; Stratford, IJ; Wheelhouse, RT; Willans, CE | 1 |
| Goodfellow, E; Jean-Claude, B; Senhaji Mouhri, Z | 1 |
| Hawkins, CJ; Miles, MA | 1 |
| Ji, Z; Xu, C; Xu, R; Zhu, J | 1 |
| Chin, AL; Deresinski, S; Gong, CL; Srinivas, S; Studdert, AL | 1 |
| Nelson, B | 1 |
| Ahtiainen, L; Bramante, S; Cerullo, V; Diaconu, I; Hemminki, A; Hemminki, O; Hirvinen, ML; Joensuu, T; Kanerva, A; Kangasniemi, L; Koski, A; Laasonen, L; Liikanen, I; Nokisalmi, P; Oksanen, M; Partanen, K; Pesonen, S; Pesonen, SK; Zhao, F | 1 |
| Camaioni, E; Ekblad, T; Macchiarulo, A; Schüler, H | 1 |
| Davidson, TB; Malogolowkin, M; Mascarenhas, L; May, W; Sposto, R; Venkatramani, R | 1 |
| De Sanctis, V; Enrici, RM; Minniti, G; Scaringi, C | 1 |
| Armand, JP; de Baere, T; Dessen, P; Lassau, N; Lazar, V; Le Berre, MA; Loriot, Y; Massard, C; Meurice, G; Peña, C; Robert, C; Robert, T; Soria, JC | 1 |
| Gupte, M; Sharma, VP; Tuck, AN; Williams, KJ | 1 |
| Blackwood, E; Del Nagro, C; Evangelista, M; Jackson, PK; Kowanetz, K; Malek, S; O'Brien, T; Ramiscal, J; Xiao, Y | 1 |
| Beelen, AP; Coker, SA; Crosby, NA; Dandamudi, UB; Ernstoff, MS; Fisher, JL; Lewis, LD; Obrocea, M | 1 |
| Abrams, JS; Conley, BA; Freidlin, B; Korn, EL; McShane, LM; Polley, MY | 1 |
| Adamson, PC; Ahern, C; Bagatell, R; Blaney, S; Fox, E; Ingle, AM; Little, AR; Norris, R; Voss, S; Weigel, BJ | 1 |
| Kapoor, S; Padhi, R; Rallabandi, VP; Roy, PK; Sakode, C | 1 |
| Aandahl, G; Dalhaug, A; Haukland, E; Marienhagen, K; Nieder, C; Pawinski, A | 1 |
| Aissat-Daudigny, L; Brown, PD; Cambois, A; Campone, M; Moachon, G; Plummer, R; Stephens, P | 1 |
| Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y | 1 |
| Cheng, Q; Jiang, AJ; Jiang, G; Li, LT; Xin, Y; Zheng, JN | 1 |
| Amaravadi, RK; Chang, YC; Davis, LE; DeMichele, AM; Evans, TL; Fecher, LA; Gallagher, M; Heitjan, DF; Kaiser, J; Kramer, A; Leone, R; Nathanson, KL; O'Dwyer, PJ; Piao, S; Pontiggia, L; Rangwala, R; Rodgers, G; Schuchter, LM; Tan, KS; Troxel, AB | 1 |
| Cheung, P; Harrison, SD; McMurry, AS; Meshaw, KR; Rainbolt, EA; Roix, JJ; Saha, S | 1 |
| Becerra, CR; Braiteh, F; Chen, J; Chow, KH; Conkling, PR; Garbo, L; Ilaria, R; Jotte, RM; Richards, DA; Robert-Vizcarrondo, F; Smith, DA; Stephenson, J; Tai, DF; Turner, PK; Von Hoff, DD | 1 |
| Armstrong, JL; Babatunde, F; Corazzari, M; Eleni Anagnostou, M; Hernandez-Tiedra, S; Hill, DS; Lopez-Valero, I; Lorente, M; Lovat, PE; McKee, CS; Redfern, CPF; Velasco, G | 1 |
| Ashcraft, KA; Boss, MK; Choudhury, KR; Dewhirst, MW; Keir, ST | 1 |
| Aquino, A; Bonmassar, E; Bonmassar, L; Caporali, S; Cioccoloni, G; D'Atri, S; Fuggetta, MP; Pagani, E | 1 |
| Kaina, B; Schirrmacher, R; Tomaszowski, KH | 1 |
| Ackermann, K; Chang, P; Chen, Z; Huang, KC; Kolber-Simonds, D; McGonigle, S; Miu, JT; Moniz, GA; Nomoto, K; Shie, JL; Twine, NC; Wu, J | 1 |
| Dullea, A; Marignol, L | 1 |
| Baryawno, N; Calero, R; Darabi, A; Dyberg, C; Einvik, C; Johnsen, JI; Kogner, P; Kool, M; Milosevic, J; Sandén, E; Siesjö, P; Sveinbjörnsson, B; Wickström, M | 1 |
| Bíró, T; Buzás, K; Endrész, V; Gyukity-Sebestyén, E; Harmati, M; Katona, RL; Kemény, L; Marton, A; Nagy, K; Németh, IB; Oláh, J; Tubak, V; Vígh, L; Vizler, C; Zvara, Á | 1 |
| Chen, TT | 1 |
| Cicchelero, L; Daminet, S; de Rooster, H; Denies, S; Polis, I; Sanders, NN; Van de Maele, I | 1 |
| Hasegawa, T | 1 |
| Korprasertthaworn, P; Lewis, BC; Miners, JO | 1 |
| Chen, CH; Chen, XY; Chen, Y; Ding, J; Gao, ZW; He, JX; He, Q; Huan, XJ; Li, XH; Liao, XM; Lu, XL; Miao, ZH; Shen, YY; Song, SS; Su, Y; Sun, YM; Tan, C; Tong, LJ; Wang, M; Wang, YQ; Wang, YT; Xiong, B; Yang, CH; Yang, XY | 1 |
| Pommier, Y; Rajapakse, VN; Reinhold, WC; Tanaka, M; Thomas, A; Trepel, J | 1 |
| Bukowski, RM; Dreicer, R; Elson, P; Mekhail, T; Olencki, T; Roman, S; Tamaskar, I | 1 |
| Hollingshead, MG | 1 |
| Boddy, A; Calvert, H; Curtin, N; Dewji, R; Evans, J; Harris, A; Johnson, P; Jones, C; McHugh, P; Middleton, M; Newell, D; Olsen, A; Plummer, R; Robson, L; Steinfeldt, H; Wang, D; Wilson, R | 1 |
| Favaudon, V; Hennequin, C; Quero, L | 1 |
| Aikin, AA; Balis, FM; Cole, DE; Fox, E; Meany, HJ; Warren, KE | 1 |
| Hwu, WJ; Patel, SP; Trinh, VA | 1 |
| Schiff, D; van den Bent, MJ; Wen, PY | 1 |
| Ali, M; Curtin, NJ; Hirst, DG; Kamjoo, M; Kyle, S; McCrudden, C; O'Rourke, M; Robson, T; Shaw, C; Telfer, BA; Thomas, HD; Williams, KJ | 1 |
| Kovach, JS; Lonser, R; Lu, J; Zhuang, Z | 1 |
| Dasgupta, A; McCarty, D; Spencer, HT | 1 |
| Adamson, PC; Ames, MM; Blaney, SM; Ingle, AM; Nelson, MD; Perentesis, JP; Reid, JM; Safgren, SL; Wagner, LM | 1 |
| Hendzel, MJ; Kaufmann, SH; Patel, A; Poirier, GG; Rouleau, M | 1 |
| Bernhard, EJ; Helleday, T; Hickson, ID; Higgins, GS; Lee, YF; McKenna, WG; Muschel, RJ; Prevo, R; Taylor, S; Yoshimura, M | 1 |
| Cheung, MC; Hicks, LK; Leitch, HA | 1 |
| Heideman, RL; McNall-Knapp, RY; Meyer, WH; Reeves, EN; Williams, CN | 1 |
| Boos, J; Brauckmann, C; Heshe, D; Hoogestraat, S; Karst, U; Lanvers-Kaminsky, C | 1 |
| Aerts, I; Chastagner, P; Chatelut, E; Corradini, N; Dias, N; Djafari, L; Frappaz, D; Gentet, JC; Geoerger, B; Landman-Parker, J; Le Deley, MC; Leblond, P; Ndiaye, A; Paci, A; Pasquet, M; Rubie, H; Schmitt, A; Vassal, G | 1 |
| Bei, R; Marzocchella, L; Turriziani, M | 1 |
| Banerjee, P; Shen, J; Wu, W; Zhou, S | 1 |
| Armand, JP; Brendel, E; Lathia, C; Ludwig, M; Robert, C; Ropert, S; Soria, JC | 1 |
| Daehler, M; Grutsch, JF; Gupta, D; Hall, JL; Levin, RD; Lis, CG | 1 |
| Cheng, J; Liu, D; Yang, JG; Zhao, LX | 1 |
| Connor, JR; Hong, YS; Lee, SY; Liu, S; Mitchell, RM; Sheehan, JM; Slagle-Webb, B | 1 |
| Burke, W; Califano, R; Carmichael, J; Gore, M; Greystoke, A; Khan, OA; Larkin, J; Lorigan, P; Margison, GP; McGown, G; Middleton, MR; Stone, J; Thorncroft, M; Watson, AJ; Wellman, S | 1 |
| Gevertz, JL | 1 |
| Barraja, P; Brun, P; Carbone, A; Castagliuolo, I; Cirrincione, G; Dall'Acqua, F; Diana, P; Issinger, OG; Parrino, B; Salvador, A; Stagno, A; Vedaldi, D | 1 |
| Kirkwood, JM; Moschos, S; Radkowski, R; Shipe-Spotloe, J; Sulecki, M; Tarhini, A; Tawbi, HA; Villaruz, L; Viverette, F | 1 |
| Chow, W; Chung, V; Cristea, M; Frankel, P; Koehler, S; Leong, L; Lim, D; Martel, C; Morgan, R; Portnow, J; Reckamp, K; Shibata, S; Synold, TW; Twardowski, P | 1 |
| Madhusudan, S | 1 |
| Dervisis, NG; Gagnon, J; Kitchell, BE | 1 |
| André, N; Bajciova, V; Deak, L; Demlova, R; Doubek, M; Dubska, L; Husek, K; Kepak, T; Kutnikova, L; Kyr, M; Martincekova, A; Mazanek, P; Mudry, P; Pavelka, Z; Skotakova, J; Sterba, J; Valik, D; Zapletalova, D; Zitterbart, K | 1 |
| Gerson, SL; Liu, L; Savvides, P; Xu, Y; Yang, S | 1 |
| Jiang, G; Li, LT; Liu, YQ; Xin, Y; Zhang, L; Zheng, JN | 1 |
| Abrial, C; Durando, X; Gadea, E; Gimbergues, P; Planchat, E; Tatar, Z; Thivat, E | 1 |
| Fortin, MA; Pouliot, JF; Roberge, D; Souhami, L | 1 |
| Lopes, IC; Oliveira, SC; Oliveira-Brett, AM | 1 |
| Arce Abaitua, B; Blumenfeld Olivares, JA; Cormenzana Carpio, M; Hernández-Marqués, C; Lassaletta-Atienza, A; Madero Lopez, L; Ruiz Hernández, A | 1 |
| Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Kurmasheva, RT; Lock, R; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA; Wu, J | 1 |
| Billups, C; Cheshire, PJ; Fouladi, M; Friedman, HS; Houghton, PJ; Leggas, M; Peterson, JK; Stewart, CF; Woo, MH | 1 |
| Howell, SJ; Shalet, SM | 1 |
| Günay, U; Meral, A; Ozkan, T; Ozuysal, S; Sevinir, B; Sinirtas, M | 1 |
| Baldwin, A; Huang, Z; Jounaidi, Y; Waxman, DJ | 1 |
| Burris, HA; Gian, VG; Greco, FA; Hainsworth, JD; Jones, SF; Miranda, FT; Shipley, DL; Thompson, DS; Toomey, MA; Willcutt, NT | 1 |
| Kéri, G; Szende, B | 1 |
| Baker, SD; Batra, VK; Cutler, DL; Donehower, RC; Rudek, MA; Statkevich, P | 1 |
| Albritton, K; Crews, KR; Fuller, CE; Goldsby, RE; Houghton, PJ; Iacono, LC; McCarville, MB; Santana, VM; Stewart, CF; Wagner, LM | 1 |
| Campbell, E; Drengler, RL; Eckardt, JR; Gerson, SL; Hammond, LA; Johnson, T; Kuhn, JG; Rowinsky, EK; Smith, L; Von Hoff, DD; Weiss, GR | 1 |
| Liang, H; Sha, N | 1 |
| Awada, A; de Valeriola, D; Dubuisson, M; Gil, T; Klastersky, J; Moerman, C; Piccart, MJ; Sales, F; Vereecken, P | 1 |
| Piro, LD | 1 |
| Middleton, MR; Payne, MJ; Pratap, SE | 1 |
| Curtin, NJ | 1 |
| Graziani, G; Tentori, L | 1 |
| Castellano, A; De Sio, L; Dominici, C; Donfrancesco, A; Fidani, P; Jenkner, A; Milano, GM | 1 |
| Birner, A | 1 |
| Beschorner, AF; Burris, HA; Gian, VG; Greco, FA; Hainsworth, JD; Jones, SF; Kennerly, G; Miranda, FT; Raefsky, EL; Willcutt, NT | 1 |
| Chastagner, P; Couanet, D; Djafari, L; Doz, F; Frappaz, D; Gentet, JC; Geoerger, B; Geoffray, A; Margison, GP; O'Quigley, J; Pein, F; Raquin, MA; Rubie, H; Vassal, G; Wartelle, M; Watson, AJ | 1 |
| Aikin, AA; Balis, FM; Fox, E; Libucha, M; Packer, RJ; Warren, KE; Widemann, BC | 1 |
| Bridgewater, J; Dawson, M; Donnelly, D; Gumbrell, L; Halbert, G; Jowle, D; Lee, SM; Margison, GP; McElhinney, RS; McGrath, H; McMurry, TB; Middleton, MR; Ranson, M; Waller, S | 1 |
| Marx, J | 1 |
| Middleton, MR; Sabharwal, A | 1 |
| Eoh, W; Kang, CM; Kim, JS; Kim, JT; Kim, MH; Ko, KW; Kong, DS; Lee, DS; Nam, DH; Shin, HJ; Son, MJ; Song, HS | 1 |
| Bajciova, V; Kadlecova, V; Kepak, T; Mazanek, P; Mudry, P; Pavelka, Z; Sterba, J; Valik, D; Zitterbart, K | 1 |
| Ribatti, D | 1 |
| Khan, MI; Kloecker, GH; Laber, DA; Salvador, C; Schonard, C; Taft, BS | 1 |
| Sinkovics, J | 1 |
| Burgess, TL; Coxon, A; Jun, HT; Kendall, R; Radinsky, R; Rex, K; Sun, J | 1 |
| Facchini, V; Kiss, R; Lefranc, F | 1 |
| Bychkov, MB; Perevodchikova, NI | 1 |
| Boon, T | 1 |
| Elliott, RS; Harrison, WH; Haskell, CM; Kaiser, LR; Morton, DL; Ramming, KR; Sarna, G; Silberman, AW; Storm, FK | 1 |
| Bogden, AE; Cobb, WR; Costanza, ME; Griffin, W; Reich, SD | 1 |
| Bonmassar, E; Fioretti, MC; Romani, L | 1 |
| Buesa, JM; Estrada, E; Gracia, M; Hidalgo, OF; Lacave, AJ; Valle, M | 1 |
| Campbell, ED; Carter, WH; Stablein, DM; Wampler, GL | 1 |
| Levitt, DZ | 1 |
| Bamberg, M; Holfeld, H | 1 |
| Liter, ME | 1 |
| Bedikian, AY; Luna, M; Mackay, B; Valdivieso, M | 1 |
| Dolan, ME; Janisch, L; Mitchell, RB; Ratain, MJ; Schilsky, RL; Vogelzang, NJ | 1 |
| Försti, A; Hemminki, K; Hietanen, P; Mustonen, R | 2 |
| Calvert, AH; Carmichael, J; Foster, BJ; Goodard, PM; Gumbrell, LA; Harris, AL; Jones, M; Newell, DR | 1 |
| Anderson, PM; Skubitz, KM | 1 |
| Balcerzak, SP; Benzies, T; Triozzi, PL; Tucker, F | 1 |
| Newlands, ES; Porteous, JK; Wedge, SR | 1 |
| Amstutz, P; Moyo, JS | 1 |
| Ames, MM; Ettinger, AG; Krailo, M; Liu-Mares, W; Nicholson, HS; Reaman, GH; Reid, JM; Seibel, NL; Vezina, LG | 1 |
| Ablett, S; Batra, V; Dicks-Mireaux, C; Dugan, M; Estlin, EJ; Gholkar, A; Gowing, R; Kohler, J; Lashford, L; Lewis, IJ; Marco, A; McDowell, H; Morland, B; Mott, M; Newell, DR; Pearson, AD; Pinkerton, CR; Price, L; Reidenberg, P; Statkevich, P; Stevens, MC; Stevens, R; Walker, D | 1 |
| Bower, M; Brampton, MH; Brock, CS; Colquhoun, I; Evans, H; Glaser, M; Newlands, ES; Roddie, M; Rustin, GJ; Wedge, SR | 1 |
| Ames, MM; Reid, JM; Rubin, J; Stevens, DC | 1 |
| Ames, MM; Buckner, JC; Burch, PA; Dhodapkar, M; Pitot, HC; Reid, JM; Rubin, J; Suman, VJ | 1 |
| Berger, D; Bonfanti, M; D'Incalci, M; Fiebig, HH; Mascellani, E; Pifferi, A; Tagliabue, G | 1 |
| Alton, K; Baker, SD; Batra, V; Cutler, D; Donehower, RC; Dugan, M; Grochow, LB; Reidenberg, P; Rowinsky, EK; Sartorius, SE; Statkevich, P; Wirth, M | 1 |
| Agarwala, SS; Baker, SD; Barrington, R; Britten, CD; Diab, SG; Eckardt, JR; Eckhardt, SG; Fraass, U; Hammond, LA; Johnson, T; Rowinsky, EK; Statkevich, P; Villalona-Calero, M; Von Hoff, DD | 1 |
| Beale, P; Brada, M; Cutler, DL; Judson, I; Marco, A; Moore, S; Reidenberg, P; Statkevich, P | 1 |
| Baker, SD; Dugan, M; Eckardt, JR; Eckhardt, SG; Forral, K; Hammond, LA; Reidenberg, P; Rinaldi, DA; Rowinsky, EK; Statkevich, P; Von Hoff, DD; Weiss, GR | 1 |
| Batra, V; Beale, P; Brada, M; Cutler, D; Dugan, M; Judson, I; Moore, S; Reidenberg, P; Statkevich, P | 1 |
| Hoff, PM; Pazdur, R; Royce, ME | 1 |
| Affrime, MB; Batra, VK; Cutler, DL; Hajian, G; Heft, S; Jen, JF; Pai, SM; Zambas, DN | 1 |
| Gerson, SL; Haaga, J; Liu, L; Majka, S; Spiro, TP; Willson, JK | 1 |
| Banerjee, D | 1 |
| Lichtman, SM; Skirvin, JA | 1 |
| Kashmin, R; Maruyama, Y; Meeker, WR; Moses, B; Vider, M | 1 |
| Salem, PA | 1 |
| Cohen, FB; Custodio, MC; Decter, JA; Lippman, AJ | 1 |
| Chabner, BA; Myers, CE; Oliverio, VT | 1 |
| Carter, SK; Slavik, M | 1 |
| Cavalli, F | 1 |
| Rosenberg, SA | 1 |
| Goldin, A; Houchens, DP | 1 |
| Cox, PJ; Farmer, PB | 1 |
| Aranha, GV; Grage, TB; Gunnarsson, A; McKhann, CF; Simmons, RL | 1 |
| Harvey, HA; Hepner, GW; Lipton, A; White, DS | 1 |
| Kokron, O; Pridun, N; Zischinsky, W | 1 |
| Bonmassar, E; Goldin, A; Nicolin, A | 1 |
| Slavik, M | 1 |
| Carter, SK | 1 |
| Cruz, AB; Davis, HL; Fletcher, WS; Golomb, FM; Grage, T; Hill, GJ; Johnson, RO; Metter, G; Wilson, WL | 1 |
| Cappelaere, P | 1 |
| Klahr, C; Presant, CA | 1 |
| Cangir, A; Land, VJ; Morgan, SK; Nitschke, R; Pullen, J; Starling, SA | 1 |
| Gutterman, JU; Hersh, EM; Mavligit, GM | 1 |
| Dickey, C; Gerner, RE; Moore, GE | 1 |
| Meiselbaugh, D; Moore, GE | 1 |
| Weiss, RB | 1 |
| Blackledge, GR; Brampton, MH; Hoffman, R; Newlands, ES; Quarterman, CP; Rustin, GJ; Slack, JA; Smith, DB; Stevens, MF; Stuart, NS | 1 |
| Chaitchik, S; Inbar, M; Merimsky, O; Ron, I; Shiloni, E | 1 |
| Coldman, AJ; Goldie, JH | 1 |
| Bleyer, WA | 1 |
| Wilman, DE | 1 |
| Giraldi, T; Perissin, L; Sava, G; Zorzet, S | 1 |
| Pályi, I | 1 |
| Maynard, K; Parsons, PG | 1 |
| Golovinsky, EV; Spassova, MK | 1 |
| Ogawa, M | 1 |
38 review(s) available for dacarbazine and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
Estimating the global burden of Epstein-Barr virus-related cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Burkitt Lymphoma; Dacarbazine; Doxorubicin; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Hodgkin Disease; Humans; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms; Stomach Neoplasms; Vinblastine | 2022 |
An overview of current results with the vincristine-irinotecan-temozolomide combination with or without bevacizumab in pediatric, adolescence and adult solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Dacarbazine; Humans; Irinotecan; Neoplasms; Temozolomide; Vincristine | 2021 |
The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Clinical Trials as Topic; Dacarbazine; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Hydroxychloroquine; Neoplasms; Risk; Temozolomide; Treatment Outcome | 2018 |
PARP inhibitors: polypharmacology versus selective inhibition.
Topics: Amino Acid Motifs; Animals; Antineoplastic Agents; Catalytic Domain; Clinical Trials as Topic; Dacarbazine; Humans; Indoles; Models, Molecular; Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 2013 |
Temozolomide-related hematologic toxicity.
Topics: Antineoplastic Agents, Alkylating; Comorbidity; Dacarbazine; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Hematologic Diseases; Humans; Incidence; Neoplasms; Risk Factors; Temozolomide; Treatment Outcome | 2013 |
Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Research; Temozolomide | 2014 |
MGMT testing allows for personalised therapy in the temozolomide era.
Topics: Aged; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; Gene Silencing; Humans; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Precision Medicine; Promoter Regions, Genetic; Reproducibility of Results; Temozolomide; Treatment Outcome | 2016 |
Temozolomide in the Era of Precision Medicine.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Humans; Neoplasms; Precision Medicine; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2017 |
[Biological basis of chemo-radiotherapy associations].
Topics: Cell Proliferation; Cisplatin; Combined Modality Therapy; Dacarbazine; Deoxycytidine; DNA Damage; DNA Repair; Fluorouracil; Gemcitabine; Humans; Neoplasms; Oxygen Consumption; Radiation Tolerance; Temozolomide | 2009 |
The safety of temozolomide in the treatment of malignancies.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Humans; Lymphopenia; Nausea; Neoplasms; Neutropenia; Radiotherapy; Temozolomide; Thrombocytopenia; Vomiting | 2009 |
Neurological adverse effects caused by cytotoxic and targeted therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dacarbazine; Drug Approval; Epothilones; Humans; Imatinib Mesylate; Indoles; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Piperazines; Pyrazines; Pyrimidines; Pyrroles; Sunitinib; Temozolomide; Tubulin Modulators; United States; United States Food and Drug Administration | 2009 |
PARP inhibition: PARP1 and beyond.
Topics: Animals; Antineoplastic Agents; Cell Death; Dacarbazine; Deoxycytidine; DNA Damage; DNA, Neoplasm; Gemcitabine; Humans; Kinetics; Mice; Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Substrate Specificity; Temozolomide | 2010 |
The use of temozolomide for the treatment of malignant tumors: clinical evidence and molecular mechanisms of action.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy, Combination; Humans; Neoplasms; Temozolomide | 2010 |
Strategies to improve the killing of tumors using temozolomide: targeting the DNA repair protein MGMT.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Humans; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Oncolytic Viruses; RNA Interference; Temozolomide | 2012 |
Temozolomide and unusual indications: review of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Melanoma; Neoplasms; Neuroendocrine Tumors; Pituitary Neoplasms; Temozolomide | 2013 |
Effect of cancer therapy on pituitary-testicular axis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Humans; Male; Neoplasms; Pituitary Gland; Radiotherapy; Testis; Vinblastine | 2002 |
TT-232: a somatostatin structural derivative as a potent antitumor drug candidate.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Dacarbazine; Etoposide; Humans; Neoplasms; Peptides, Cyclic; Somatostatin | 2003 |
Apoptosis, Bcl-2 antisense, and cancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Genes, bcl-2; Humans; Melanoma; Neoplasms; Oligonucleotides, Antisense; Proto-Oncogene Mas; Proto-Oncogene Proteins c-bcl-2; Randomized Controlled Trials as Topic; Thionucleotides; Transplantation, Heterologous | 2004 |
Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Dacarbazine; DNA Repair; Drug Administration Schedule; Humans; Neoplasms; Temozolomide; Treatment Outcome | 2005 |
PARP inhibitors for cancer therapy.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Dacarbazine; DNA Repair; DNA, Neoplasm; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Mice; Mice, Knockout; Neoplasm Proteins; Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Radiation Tolerance; Temozolomide | 2005 |
Chemopotentiation by PARP inhibitors in cancer therapy.
Topics: Animals; Antineoplastic Agents; Dacarbazine; DNA Damage; Drug Synergism; Enzyme Inhibitors; Humans; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2005 |
Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dacarbazine; DNA Adducts; DNA Methylation; DNA Topoisomerases, Type I; Drug Administration Schedule; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Guanine; Humans; Irinotecan; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Organoplatinum Compounds; Prognosis; Promoter Regions, Genetic; Temozolomide; Topoisomerase I Inhibitors | 2006 |
Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Dacarbazine; Drug Delivery Systems; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplasms; Temozolomide | 2007 |
Antigenic tumor cell variants obtained with mutagens.
Topics: Animals; Antigens, Neoplasm; Cells, Cultured; Dacarbazine; Histocompatibility Antigens; Humans; Immunization; Leukemia L1210; Methylnitronitrosoguanidine; Mice; Mice, Inbred Strains; Mutagens; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Teratoma; Transplantation Immunology | 1983 |
[Disseminated intravascular coagulations].
Topics: Blood Coagulation; Blood Coagulation Tests; Dacarbazine; Diagnosis, Differential; Female; Humans; Male; Neoplasms; Pregnancy; Pregnancy Complications, Hematologic; Shock, Septic | 1996 |
Novel oral chemotherapy agents.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasms; Tegafur; Temozolomide; Uracil | 2000 |
Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Complementary Therapies; Cytochrome P-450 Enzyme System; Dacarbazine; Etoposide; Humans; Idarubicin; Neoplasms; Tamoxifen; Temozolomide; Thalidomide; Topotecan | 2002 |
Advances in cancer chemotherapy.
Topics: Bleomycin; Burkitt Lymphoma; Carcinoma, Basal Cell; Choriocarcinoma; Cyclophosphamide; Cytarabine; Dacarbazine; Doxorubicin; Female; Humans; Lomustine; Lung Neoplasms; Methotrexate; Mitosis; Neoplasms; Pregnancy; Skin Neoplasms; Vincristine | 1975 |
New antineoplastic drugs and their proper use.
Topics: Antineoplastic Agents; Asparaginase; Azacitidine; Bleomycin; Bone Marrow Diseases; Dacarbazine; Doxorubicin; Humans; Liver; Nausea; Neoplasms; Nitrosourea Compounds; Pancreatitis; Pulmonary Fibrosis; Vomiting | 1976 |
Current investigational drugs of interest in the Chemotherapy Program of the National Cancer Institute.
Topics: Altretamine; Animals; Antineoplastic Agents; Asparaginase; Azacitidine; Bleomycin; Cisplatin; Dacarbazine; Doxorubicin; Drug Evaluation; Female; Guanazole; Humans; Ifosfamide; Male; National Institutes of Health (U.S.); Neoplasms; Nitrogen Mustard Compounds; Nitrosourea Compounds; Razoxane; United States | 1977 |
[New substances in oncologic therapy].
Topics: Alkylating Agents; Altretamine; Antimetabolites, Antineoplastic; Cisplatin; Dacarbazine; Doxorubicin; Drug Evaluation; Drug Evaluation, Preclinical; Etoposide; Humans; Neoplasms; Nitrosourea Compounds; Razoxane; Tamoxifen; Vinca Alkaloids; Zinostatin | 1978 |
Chemotherapy modalities and immune condition of the host.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; BCG Vaccine; Dacarbazine; Drug Resistance; Immunity; Immunization; Immunization, Passive; Leukemia L1210; Lymphocytes; Mice; Neoplasms; Neuraminidase | 1978 |
Towards selectivity? Approaches to the design of new anti-tumour agents--II.
Topics: Altretamine; Amino Acids; Antineoplastic Agents; Carbohydrates; Chelating Agents; Colchicine; Coloring Agents; Dacarbazine; Daunorubicin; Doxorubicin; Drug Interactions; Ellipticines; Folic Acid Antagonists; Heart Diseases; Humans; Lectins; Neoplasms; Nitrosourea Compounds; Peptide Hydrolases; Podophyllotoxin; Polymers; Structure-Activity Relationship | 1977 |
Immunotherapy of cancer in man: current status and prospectus.
Topics: Antineoplastic Agents; BCG Vaccine; Dacarbazine; Humans; Immunity; Immunity, Maternally-Acquired; Immunotherapy; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Neoplasms; Propionibacterium acnes; Remission, Spontaneous | 1976 |
Hypersensitivity reactions.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Aziridines; Benzoquinones; Bleomycin; Chlorambucil; Cisplatin; Cyclophosphamide; Cytarabine; Dacarbazine; Drug Hypersensitivity; Etoposide; Fluorouracil; Humans; Ifosfamide; Melphalan; Methotrexate; Mitomycins; Neoplasms; Paclitaxel; Pentostatin; Procarbazine; Teniposide | 1992 |
Cancer chemotherapy in infants and children.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Bleomycin; Catheters, Indwelling; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Cytarabine; Dacarbazine; Dactinomycin; Daunorubicin; Doxorubicin; Humans; Infant; Infant, Newborn; Infusions, Parenteral; Mercaptopurine; Methotrexate; Neoplasms; Nitrosourea Compounds; Thioguanine; Vinblastine; Vincristine | 1985 |
Pharmacobiochemistry of arylalkyltriazenes and their application in cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Biotransformation; Carcinogens; Dacarbazine; Humans; Mutagens; Neoplasms; Structure-Activity Relationship; Triazenes | 1985 |
52 trial(s) available for dacarbazine and Benign Neoplasms
| Article | Year |
|---|---|
A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Child; Child, Preschool; Dacarbazine; Humans; Irinotecan; Maximum Tolerated Dose; Metformin; Neoplasm Recurrence, Local; Neoplasms; Sarcoma, Ewing; Temozolomide; Vincristine | 2023 |
A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Child; Child, Preschool; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Recurrence; Temozolomide; Vincristine; Young Adult | 2013 |
Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Genomics; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Ultrasonography | 2014 |
A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Polyethylene Glycols; Recombinant Proteins; Temozolomide; Treatment Outcome | 2013 |
Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Follow-Up Studies; Humans; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Prognosis; Remission Induction; Sirolimus; Temozolomide; Young Adult | 2014 |
Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalimides; Poly(ADP-ribose) Polymerase Inhibitors; Prodrugs; Prognosis; Temozolomide; Tissue Distribution; Young Adult | 2014 |
Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Doxorubicin; Electric Stimulation Therapy; Epirubicin; Humans; Ifosfamide; Isoquinolines; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting; Young Adult | 2014 |
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Male; Melanoma; Middle Aged; Neoplasm Staging; Neoplasms; Temozolomide; Treatment Outcome | 2014 |
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Sulfonamides; Taxoids; Temozolomide; Young Adult | 2015 |
Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Survival Rate; Taxoids; Temozolomide | 2008 |
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Comet Assay; Cytochrome P-450 CYP2D6; Dacarbazine; DNA Breaks; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Temozolomide | 2008 |
Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromatography, High Pressure Liquid; Dacarbazine; Dose-Response Relationship, Drug; Drug Interactions; Female; Guanine; Hematologic Diseases; Humans; Male; Neoplasms; Sex Factors; Tandem Mass Spectrometry; Temozolomide; Young Adult | 2009 |
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasms; Temozolomide; Vincristine; Young Adult | 2010 |
Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Temozolomide; Vincristine; Young Adult | 2010 |
Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbazine; Humans; Infant; Neoplasm Recurrence, Local; Neoplasms; Temozolomide; Topotecan; Treatment Outcome; Tumor Protein, Translationally-Controlled 1; Young Adult | 2010 |
Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.
Topics: Aminoimidazole Carboxamide; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease Progression; Female; Humans; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia.
Topics: Adult; Aged; Antineoplastic Agents; Blood Platelets; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Escherichia coli; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasms; RNA; Thrombocytopenia; Treatment Outcome | 2010 |
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasms; Neutropenia; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Thrombocytopenia | 2011 |
Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Purines | 2011 |
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Induction; Fatigue; Female; Humans; Liver; Lymphopenia; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Pyrazines; Temozolomide; Treatment Outcome; Young Adult | 2012 |
Chemosensitized radiosurgery for recurrent brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Pilot Projects; Prognosis; Radiosurgery; Survival Rate; Temozolomide | 2012 |
Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Temozolomide; Treatment Outcome | 2003 |
Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study.
Topics: Administration, Oral; Adult; Aged; Alkaline Phosphatase; Alkylating Agents; Area Under Curve; Bilirubin; Capsules; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Half-Life; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Temozolomide; Thrombocytopenia; Tissue Distribution; Treatment Failure | 2004 |
Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Base Pair Mismatch; Camptothecin; Cell Line, Tumor; Child; Child, Preschool; Dacarbazine; DNA Repair; Female; Humans; Immunohistochemistry; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Temozolomide; Time Factors | 2004 |
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Neutrophils; Temozolomide | 2004 |
Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Stomatitis; Temozolomide; Treatment Outcome | 2004 |
Temozolomide in resistant or relapsed pediatric solid tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Male; Neoplasm Recurrence, Local; Neoplasms; Survival Analysis; Temozolomide | 2006 |
A Phase I trial of protracted oral fixed-dose temozolomide.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Temozolomide; Treatment Outcome | 2005 |
Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Female; Humans; Infant; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Salvage Therapy; Temozolomide; Treatment Outcome | 2005 |
Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Guanine; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Neoplasms; Prognosis; Temozolomide | 2005 |
Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
Topics: Adenosine Triphosphatases; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Guanine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Safety; Temozolomide | 2006 |
Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study.
Topics: Administration, Oral; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Child, Preschool; Dacarbazine; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Male; Neoplasm Recurrence, Local; Neoplasms; Pilot Projects; Pyrazoles; Sulfonamides; Temozolomide; Treatment Outcome; Tretinoin | 2006 |
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Temozolomide; Thalidomide; Treatment Outcome | 2007 |
Clinical thermochemotherapy. A controlled trial in advanced cancer patients.
Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Female; Fluorouracil; Follow-Up Studies; Hot Temperature; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Metastasis; Neoplasms | 1984 |
Sequential therapy with dacarbazine and carmustine: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Methyltransferases; Middle Aged; Monocytes; Neoplasms; Neutropenia; O(6)-Methylguanine-DNA Methyltransferase; Thrombocytopenia | 1994 |
Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Dacarbazine; Disease Models, Animal; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasms; Species Specificity; Transplantation, Heterologous; Triazenes | 1993 |
Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cyclophosphamide; Dacarbazine; Double-Blind Method; Doxorubicin; Etoposide; Female; Fluorouracil; Glutamine; Humans; Ifosfamide; Male; Neoplasms; Pilot Projects; Placebos; Sarcoma, Kaposi; Stomatitis; Vincristine | 1996 |
Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor.
Topics: Adult; Aged; Antigen-Presenting Cells; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Blood Preservation; Bone Marrow; Bone Marrow Diseases; Combined Modality Therapy; Cryopreservation; Cytotoxicity, Immunologic; Dacarbazine; Doxorubicin; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Ifosfamide; Interferon-gamma; Interleukin-2; Leukapheresis; Macrophages; Male; Middle Aged; Monocytes; Neoplasms; Recombinant Proteins; Tetanus Toxoid; Time Factors; Tumor Cells, Cultured | 1996 |
Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Male; Neoplasm Recurrence, Local; Neoplasms; Temozolomide | 1998 |
Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Cranial Irradiation; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Neoplasms; Nitrosourea Compounds; Remission Induction; Temozolomide | 1998 |
Phase I trial of temozolomide using an extended continuous oral schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration; Chromatography, High Pressure Liquid; Dacarbazine; Drug Administration Schedule; England; Female; Glioma; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Temozolomide | 1998 |
Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.
Topics: Adult; Alkylating Agents; Antineoplastic Agents, Alkylating; Chromatography, High Pressure Liquid; Dacarbazine; Half-Life; Humans; Metabolic Clearance Rate; Neoplasms; Regression Analysis; Temozolomide | 1997 |
Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Regression Analysis; Temozolomide | 1997 |
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
Topics: Absorption; Administration, Oral; Adult; Aged; Aminoimidazole Carboxamide; Antineoplastic Agents, Alkylating; Blood Proteins; Carbon Radioisotopes; Dacarbazine; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Temozolomide | 1999 |
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nausea; Neoplasm Staging; Neoplasms; Neutropenia; Temozolomide; Treatment Outcome; Vomiting | 1999 |
Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Ulcer Agents; Antineoplastic Agents, Alkylating; Biological Availability; Dacarbazine; Female; Gastric Acid; Gastric Acidity Determination; Humans; Male; Middle Aged; Neoplasms; Ranitidine; Temozolomide | 1999 |
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Dacarbazine; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Temozolomide | 1999 |
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Eating; Female; Glioma; Humans; Male; Melanoma; Middle Aged; Neoplasms; Skin Neoplasms; Temozolomide; Treatment Outcome | 1999 |
Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Area Under Curve; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasms; Neutropenia; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Thrombocytopenia; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2001 |
Clinical studies with DTIC (NSC-45388) in various malignancies.
Topics: Adult; Carmustine; Child; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasms; Neuroblastoma; Rhabdomyosarcoma; Triazenes; Vincristine | 1976 |
Combination chemotherapy in disseminated melanoma and other solid tumors in adults.
Topics: Clinical Trials as Topic; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Humans; Lomustine; Melanoma; Neoplasms; Nitrosourea Compounds; Triazenes | 1975 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Glioma; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Stomach Neoplasms; Temozolomide | 1992 |
91 other study(ies) available for dacarbazine and Benign Neoplasms
| Article | Year |
|---|---|
Late side effects of cancer treatment in childhood cancer survivors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cancer Survivors; Child; Child, Preschool; Dacarbazine; Doxorubicin; Female; Hodgkin Disease; Humans; Male; Neoplasms; Quality of Life; Retrospective Studies; Vinblastine; Young Adult | 2023 |
Core-Shell Reactor Partitioning Enzyme and Prodrug by ZIF-8 for NADPH-Sensitive In Situ Prodrug Activation.
Topics: Antineoplastic Agents; Cytochrome P-450 Enzyme System; Dacarbazine; Humans; NADP; Neoplasms; Prodrugs | 2023 |
Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Dacarbazine; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Glycolysis; Humans; Imidazoles; Inhibitory Concentration 50; Neoplasms; Organometallic Compounds; Oxidative Stress; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Reactive Oxygen Species; Signal Transduction; Temozolomide; Thioredoxin Reductase 1; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2017 |
A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; Cricetulus; Dacarbazine; DNA Repair; DNA, Neoplasm; Guanine; Humans; Mutation; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide | 2017 |
Executioner caspases and CAD are essential for mutagenesis induced by TRAIL or vincristine.
Topics: Apoptosis; Aspartate Carbamoyltransferase; Camptothecin; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; Dacarbazine; Dihydroorotase; DNA Damage; Doxorubicin; Enzyme Activation; Humans; Irinotecan; Mutagenesis; Mutation; Neoplasms; Signal Transduction; Temozolomide; TNF-Related Apoptosis-Inducing Ligand; Vincristine | 2017 |
Application of pharmacoeconomics to formulary management in a health system setting.
Topics: Academic Medical Centers; Clinical Trials as Topic; Cost-Benefit Analysis; Dacarbazine; Drug Approval; Drug Costs; Drug Utilization Review; Economics, Pharmaceutical; Formularies as Topic; Humans; Interdisciplinary Communication; Markov Chains; Models, Economic; Neoplasms; Pharmaceutical Services; Pharmacy and Therapeutics Committee; Trabectedin; Treatment Outcome; United States; United States Food and Drug Administration | 2019 |
Targeting a murky cancer reservoir: more researchers set their sights on cancer stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Forecasting; Ganciclovir; Humans; Mice; Molecular Targeted Therapy; Neoplasms; Neoplastic Stem Cells; Research Personnel; Temozolomide | 2013 |
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
Topics: Adenosine Triphosphate; Adenoviridae; Adolescent; Adult; Aged; Animals; Antibodies, Neutralizing; Antineoplastic Agents; Autophagy; Calreticulin; Cell Death; Cell Line, Tumor; Child; Combined Modality Therapy; Cyclophosphamide; Cytokines; Dacarbazine; DNA, Viral; Dose-Response Relationship, Drug; Female; HMGB1 Protein; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Microscopy, Electron; Middle Aged; Neoplasms; Oncolytic Virotherapy; Oncolytic Viruses; T-Lymphocytes, Regulatory; Temozolomide; Virus Replication; Xenograft Model Antitumor Assays; Young Adult | 2013 |
Major differences between tumor and normal human cell fates after exposure to chemotherapeutic monofunctional alkylator.
Topics: Antineoplastic Agents, Alkylating; Apoptosis Inducing Factor; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Lineage; Dacarbazine; Electrophoretic Mobility Shift Assay; Fluorescent Antibody Technique, Indirect; Humans; Methylnitronitrosoguanidine; Neoplasm Proteins; Neoplasms; Temozolomide | 2013 |
Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbolines; Cell Cycle Checkpoints; Checkpoint Kinase 1; Dacarbazine; Deoxycytidine; DNA Damage; Gemcitabine; HCT116 Cells; High-Throughput Nucleotide Sequencing; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Indazoles; Interleukin-6; Kidney Neoplasms; Lung Neoplasms; Methylation; Molecular Targeted Therapy; Mutation; Neoplasms; Precision Medicine; Predictive Value of Tests; Pyrimidines; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sample Size; Sulfonamides; Temozolomide; Tumor Suppressor Proteins | 2013 |
A patient-specific therapeutic approach for tumour cell population extinction and drug toxicity reduction using control systems-based dose-profile design.
Topics: Antineoplastic Agents; Combined Modality Therapy; Computer Simulation; Dacarbazine; Dose-Response Relationship, Drug; Glioma; Humans; Immunotherapy; Magnetic Resonance Imaging; Neoplasm Grading; Neoplasms; Precision Medicine; Remission Induction; Temozolomide; Translational Research, Biomedical | 2013 |
Impact of systemic treatment on survival after whole brain radiotherapy in patients with brain metastases.
Topics: Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Temozolomide; Treatment Outcome | 2014 |
Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Dacarbazine; Drug Approval; Drug Repositioning; Etidronic Acid; Female; High-Throughput Screening Assays; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Neoplasms; Risedronic Acid; Temozolomide; Tetrazoles; Xenograft Model Antitumor Assays | 2014 |
Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cannabidiol; Cannabinoids; Cannabinol; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Dronabinol; Drug Combinations; Humans; Male; Melanoma; Membrane Proteins; Mice; Mice, Nude; Microscopy, Confocal; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Plant Extracts; Proto-Oncogene Proteins B-raf; ras Proteins; Skin Neoplasms; Temozolomide | 2015 |
Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies.
Topics: Animals; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Neoplasms; Temozolomide; Therapies, Investigational; Tissue Distribution | 2015 |
Influence of fatty acid synthase inhibitor orlistat on the DNA repair enzyme O6-methylguanine-DNA methyltransferase in human normal or malignant cells in vitro.
Topics: Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Enzyme Inhibitors; HCT116 Cells; HT29 Cells; Humans; In Vitro Techniques; Lactones; Leukocytes, Mononuclear; Neoplasms; Orlistat; Purines; Temozolomide; Tumor Suppressor Proteins | 2015 |
Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP-Binding Cassette Transporters; Blotting, Western; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorescent Antibody Technique; Glucose; Humans; Neoplasms; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2015 |
E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azo Compounds; Blotting, Western; Carboplatin; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Repair; DNA-Binding Proteins; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Isoquinolines; Mice, Inbred C57BL; Mice, Nude; Mice, SCID; Neoplasms; Neoplasms, Experimental; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolinones; Reverse Transcriptase Polymerase Chain Reaction; Tankyrases; Temozolomide; Tumor Burden; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2015 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Celecoxib; Cisplatin; Colorectal Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Glucose-6-Phosphate Isomerase; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Immunohistochemistry; Irinotecan; Medulloblastoma; Mice; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Pyrans; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Sulfones; Temozolomide; Triazoles; Tumor Suppressor Proteins; Vincristine; Wnt Proteins; Wnt Signaling Pathway | 2015 |
Bacterial Sepsis Increases Survival in Metastatic Melanoma: Chlamydophila Pneumoniae Induces Macrophage Polarization and Tumor Regression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlamydophila Infections; Chlamydophila pneumoniae; Dacarbazine; Humans; Lomustine; Lung Neoplasms; Macrophage Activation; Macrophages; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasms; Sepsis; Skin Neoplasms; Treatment Outcome; Vincristine | 2016 |
Predicting analysis times in randomized clinical trials with cancer immunotherapy.
Topics: Algorithms; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dacarbazine; Humans; Immunotherapy; Ipilimumab; Kaplan-Meier Estimate; Melanoma; Models, Theoretical; Neoplasms; Outcome Assessment, Health Care; Prognosis; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Retrospective Studies; Time Factors | 2016 |
Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients.
Topics: Administration, Metronomic; Animals; Antineoplastic Agents, Alkylating; Case-Control Studies; Cyclophosphamide; Dacarbazine; Dog Diseases; Dogs; Lymphocyte Count; Neoplasms; T-Lymphocytes, Regulatory; Temozolomide; Thrombospondin 1; Vascular Endothelial Growth Factor A | 2017 |
Group sequential monitoring based on the weighted log-rank test statistic with the Fleming-Harrington class of weights in cancer vaccine studies.
Topics: Antibodies, Monoclonal; Cancer Vaccines; Dacarbazine; Humans; Models, Statistical; Monte Carlo Method; Neoplasms; Nivolumab; Randomized Controlled Trials as Topic; Survival Rate | 2016 |
Impaired dacarbazine activation and 7-ethoxyresorufin deethylation in vitro by polymorphic variants of CYP1A1 and CYP1A2: implications for cancer therapy.
Topics: Antineoplastic Agents, Alkylating; Catalysis; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Dacarbazine; Humans; Neoplasms; Oxazines; Polymorphism, Single Nucleotide; Prodrugs; Substrate Specificity | 2016 |
Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; Haplorhini; Heterocyclic Compounds, 4 or More Rings; Humans; Mice; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Rats; Temozolomide; Tissue Distribution; Xenograft Model Antitumor Assays | 2017 |
Antitumor efficacy testing in rodents.
Topics: Animals; Antineoplastic Agents; Biological Availability; Dacarbazine; Data Interpretation, Statistical; Drug Approval; Drug Design; Drug Screening Assays, Antitumor; Drugs, Investigational; Endpoint Determination; Humans; Kaplan-Meier Estimate; Mice; Neoplasms; Pharmaceutical Vehicles; Random Allocation; Rats; Research Design; Rodentia; Sample Size; Tamoxifen; Temozolomide; Topotecan; Transplantation, Heterologous; United States | 2008 |
Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azulenes; Benzodiazepines; Blood Vessels; Capillary Permeability; Dacarbazine; Drug Resistance, Neoplasm; Female; HT29 Cells; Humans; Indoles; Mice; Mice, Nude; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Cycle; Dacarbazine; DNA Breaks, Double-Stranded; DNA Damage; Mice; Neoplasms; Phosphorylation; Protein Phosphatase 2; Proteome; Signal Transduction; Temozolomide; Tumor Suppressor Protein p53 | 2009 |
Engineered drug-resistant immunocompetent cells enhance tumor cell killing during a chemotherapy challenge.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cytotoxicity, Immunologic; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Genetic Engineering; Humans; Immunotherapy, Adoptive; Killer Cells, Natural; Mice; Neoplasms; Simian Immunodeficiency Virus; T-Lymphocytes; Temozolomide; Transduction, Genetic; Tumor Suppressor Proteins | 2010 |
A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Polymerase theta; DNA Repair; DNA-Directed DNA Polymerase; Gene Knockdown Techniques; HeLa Cells; Histones; Humans; Infrared Rays; Neoplasms; Radiation Tolerance; RNA, Small Interfering; Temozolomide; Transfection | 2010 |
Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; HIV Infections; Hodgkin Disease; Humans; Incidence; Lymphoma, AIDS-Related; Male; Neoplasms; Neurotoxicity Syndromes; Protease Inhibitors; Vinblastine | 2010 |
Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Dacarbazine; Dichloroacetic Acid; Doxorubicin; Drug Delivery Systems; Drug Interactions; Drug Stability; Glucose; HEK293 Cells; Humans; Membrane Potential, Mitochondrial; Neoplasms; Temozolomide | 2011 |
Core-shell hybrid nanogels for integration of optical temperature-sensing, targeted tumor cell imaging, and combined chemo-photothermal treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; Diagnostic Imaging; Mice; Microscopy, Electron, Transmission; Nanogels; Nanotechnology; Neoplasms; Phototherapy; Polyethylene Glycols; Polyethyleneimine; Temozolomide; Temperature | 2010 |
Synthesis and antitumor activity of 3-methyl-4-oxo-3,4-dihydroimidazo [5,1-d][1,2,3,5]tetrazine-8-carboxylates and -carboxamides.
Topics: Antineoplastic Agents; Dacarbazine; Drug Screening Assays, Antitumor; Heterocyclic Compounds, 2-Ring; HL-60 Cells; Humans; Neoplasms; Solubility; Temozolomide; Water | 2010 |
HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Profiling; Glioma; Hemochromatosis Protein; Histocompatibility Antigens Class I; HSP72 Heat-Shock Proteins; Humans; Membrane Proteins; NAD(P)H Dehydrogenase (Quinone); Neoplasms; Polymorphism, Genetic; Promoter Regions, Genetic; Radiation Tolerance; Temozolomide; Tumor Suppressor Proteins | 2011 |
Computational modeling of tumor response to vascular-targeting therapies--part I: validation.
Topics: Algorithms; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Vessels; Computer Simulation; Cytotoxins; Dacarbazine; Glioblastoma; Humans; Models, Biological; Neoplasms; Stilbenes; Temozolomide; Treatment Outcome | 2011 |
Synthesis of triazenoazaindoles: a new class of triazenes with antitumor activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Indoles; Neoplasms; Triazenes | 2011 |
Dacarbazine.
Topics: Animals; Antineoplastic Agents, Alkylating; Carcinogens; Dacarbazine; Humans; Neoplasms | 2011 |
Evolving drug targets in DNA base excision repair for cancer therapy.
Topics: Antineoplastic Agents, Alkylating; BRCA1 Protein; BRCA2 Protein; Dacarbazine; DNA Repair; Humans; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide | 2012 |
Treatment-related toxicities in tumor-bearing cats treated with temozolomide alone or in combination with doxorubicin: a pilot assessment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cat Diseases; Cats; Dacarbazine; Doxorubicin; Drug Administration Schedule; Maximum Tolerated Dose; Neoplasms; Neutropenia; Pilot Projects; Retrospective Studies; Stomatitis; Temozolomide | 2012 |
Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience.
Topics: Administration, Metronomic; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Child, Preschool; Dacarbazine; Etoposide; Europe; Feasibility Studies; Female; Fenofibrate; Humans; Infant; Isotretinoin; Male; Neoplasms; Pyrazoles; Registries; Sulfonamides; Temozolomide; Vitamin D; Young Adult | 2012 |
Development and validation of an LC-MS/MS method for pharmacokinetic study of methoxyamine in phase I clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzaldehydes; Chromatography, Liquid; Clinical Trials, Phase I as Topic; Dacarbazine; Drug Stability; Humans; Hydroxylamines; Linear Models; Liquid-Liquid Extraction; Neoplasms; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Temozolomide | 2012 |
In situ electrochemical evaluation of anticancer drug temozolomide and its metabolites-DNA interaction.
Topics: Aminoimidazole Carboxamide; Antineoplastic Agents, Alkylating; Biosensing Techniques; Dacarbazine; Diazonium Compounds; DNA; Electrochemical Techniques; Humans; Neoplasms; Oxidation-Reduction; Temozolomide | 2013 |
[Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors].
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasms; Retrospective Studies; Temozolomide | 2013 |
Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasm Transplantation; Neoplasms; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2013 |
Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Chromatography, High Pressure Liquid; Cyclophosphamide; Dacarbazine; Dactinomycin; Disease-Free Survival; Doxorubicin; Female; Glioblastoma; Glioma; Humans; Medulloblastoma; Mice; Mice, Inbred CBA; Mice, Inbred ICR; Mice, SCID; Neoplasms; Neuroblastoma; Neuroectodermal Tumors, Primitive; Radiation Chimera; Random Allocation; Rhabdoid Tumor; Rhabdomyosarcoma, Embryonal; Sesquiterpenes; Tumor Cells, Cultured; Vincristine; Xenograft Model Antitumor Assays | 2002 |
Increased risk of chronic hepatitis in children with cancer.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Dacarbazine; DNA, Viral; Doxorubicin; Female; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Incidence; Infant; Infant, Newborn; Liver Function Tests; Male; Neoplasms; Polymerase Chain Reaction; Risk Factors; RNA, Viral; Vinblastine | 2003 |
Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Coculture Techniques; Cyclophosphamide; Cytochrome P-450 Enzyme System; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Activation; Female; Genetic Therapy; Ifosfamide; Inhibitory Concentration 50; Ketoconazole; Liver; Male; Microsomes, Liver; Models, Chemical; Neoplasms; Procarbazine; Prodrugs; Rats; Tamoxifen; Time Factors; Troleandomycin; Tumor Cells, Cultured | 2003 |
Modeling antitumor activity by using a non-linear mixed-effects model.
Topics: Algorithms; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Computer Simulation; Dacarbazine; Data Interpretation, Statistical; Humans; Irinotecan; Mice; Neoplasms; Nonlinear Dynamics; Rhabdomyosarcoma; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2004 |
Author comments on drug-dispensing change.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neoplasms; Patient Education as Topic; Temozolomide | 2005 |
Autophagy: is it cancer's friend or foe?
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Survival; Chloroquine; Dacarbazine; Genes, Tumor Suppressor; Humans; Membrane Proteins; Mice; Neoplasms; Oncogenes; Proteins; Sirolimus; Temozolomide | 2006 |
Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Neoplasms; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley; Temozolomide | 2006 |
The contribution of Gianni Bonadonna to the history of chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Cisplatin; Dacarbazine; Doxorubicin; Female; Fluorouracil; History, 20th Century; Hodgkin Disease; Humans; Italy; Methotrexate; Neoplasms; Vinblastine | 2007 |
[The effect of oxygenation on the biological behaviour of tumours].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Hypoxia; Cell Line, Tumor; Dacarbazine; Deoxyglucose; Glioblastoma; Glycolysis; Humans; Hyperbaric Oxygenation; Kidney Neoplasms; Neoplasms; Oncogene Proteins; Oncolytic Virotherapy; Temozolomide; Transplantation, Heterologous | 2007 |
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Docetaxel; Hepatocyte Growth Factor; Humans; Mice; Mice, Inbred Strains; Neoplasms; Taxoids; Temozolomide; Xenograft Model Antitumor Assays | 2007 |
Modern problems of clinical chemotherapy of malignant tumours.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Carubicin; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Humans; Lomustine; Lung Neoplasms; Male; Melanoma; Methylnitrosourea; Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Vincristine | 1980 |
Predictive testing with the subrenal capsule assay.
Topics: Altretamine; Animals; Antineoplastic Agents; Cyclophosphamide; Dacarbazine; Drug Evaluation, Preclinical; Drug Resistance; Humans; Kidney; Mice; Necrosis; Neoplasm Transplantation; Neoplasms; Prospective Studies; Transplantation, Heterologous | 1984 |
Antigenic changes related to drug action.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Cyclophosphamide; Dacarbazine; H-2 Antigens; Immunotherapy; Mice; Neoplasms; Structure-Activity Relationship | 1983 |
Phase I trial of intermittent high-dose dacarbazine.
Topics: Adult; Aged; Dacarbazine; Digestive System; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Hypotension; Leukopenia; Male; Middle Aged; Neoplasms; Photosensitivity Disorders; Thrombocytopenia | 1984 |
Drug activity and therapeutic synergism in cancer treatment.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Melanoma; Mice; Mitomycin; Mitomycins; Neoplasms; Neoplasms, Experimental; Rats; Razoxane; Teniposide | 1982 |
Cancer chemotherapy: those dreaded side effects and what to do about them. Part five.
Topics: Antineoplastic Agents; Asparaginase; Cisplatin; Dacarbazine; Humans; Hydroxyurea; Neoplasms; Procarbazine | 1981 |
[General principles and new trends of cytostatic tumor therapy].
Topics: Antineoplastic Agents; Cisplatin; Dacarbazine; Doxorubicin; Drug Therapy, Combination; Humans; Immunotherapy; Neoplasms; Nitrosourea Compounds; Podophyllotoxin; Radiation-Sensitizing Agents; Razoxane | 1980 |
Management of drug toxicities and infections.
Topics: Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Humans; Infections; Methotrexate; Neoplasms | 1980 |
Anaplastic malignant neoplasms: diagnosis and treatment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Dacarbazine; Dactinomycin; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Prognosis; Vincristine | 1981 |
Development of a 32P-postlabeling assay for 7-methylguanines in human DNA.
Topics: Adult; Aged; Chromatography, Ion Exchange; Dacarbazine; DNA; Dose-Response Relationship, Drug; Guanine; Humans; Leukocytes; Middle Aged; Neoplasms; Oligodeoxyribonucleotides; Phosphorus Radioisotopes; Procarbazine | 1993 |
3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
Topics: Antineoplastic Agents, Alkylating; Benzamides; Carmustine; Dacarbazine; DNA Repair; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Guanine; Humans; Neoplasms; Temozolomide; Tumor Cells, Cultured | 1996 |
The antitumour activity of alkylating agents is not correlated with the levels of glutathione, glutathione transferase and O6-alkylguanine-DNA-alkyltransferase of human tumour xenografts. EORTC SPG and PAMM Groups.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Colonic Neoplasms; Cyclophosphamide; Dacarbazine; Glutathione; Glutathione Transferase; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms; Nitrosourea Compounds; Stomach Neoplasms; Transplantation, Heterologous | 1998 |
Population pharmacokinetics of temozolomide in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Body Fluid Compartments; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dacarbazine; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Neutropenia; Temozolomide; Thrombocytopenia | 2000 |
Technology evaluation: G-3139.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Dacarbazine; Docetaxel; Female; Genes, bcl-2; Genetic Therapy; Humans; Male; Mice; Mice, Inbred BALB C; National Institutes of Health (U.S.); Neoplasm Proteins; Neoplasms; Paclitaxel; Patents as Topic; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; Safety; Structure-Activity Relationship; Taxoids; Thionucleotides; Treatment Outcome; United States | 1999 |
Carcinoembryonic antigen (CEA) monitoring in the management of radiotherapeutic and chemotherapeutic patients.
Topics: Antigens, Neoplasm; Azacitidine; Carcinoembryonic Antigen; Dacarbazine; Fluorouracil; Humans; Monitoring, Physiologic; Neoplasms; Radioisotope Teletherapy | 1975 |
Clinical pharmacology of anticancer drugs.
Topics: Animals; Antineoplastic Agents; Azacitidine; Bleomycin; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Doxorubicin; Female; Fluorouracil; Heart; Humans; Leucovorin; Lung; Male; Methotrexate; Neoplasms; Nitrosourea Compounds; Procarbazine; Triazenes; Vinblastine; Vincristine | 1977 |
Future prospects for immunotherapy.
Topics: Animals; BCG Vaccine; Carcinoma, Hepatocellular; Dacarbazine; Guinea Pigs; Humans; Immunotherapy; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Liver Neoplasms; Melanoma; Methotrexate; Mice; Neoplasms; Neoplasms, Experimental; Sarcoma | 1975 |
Adjuvant immunotherapy of malignant melanoma.
Topics: BCG Vaccine; Cholera Vaccines; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Neoplasm Staging; Neoplasms; Neuraminidase; Vibrio cholerae | 1979 |
Decreased hepatic drug demethylation in patients receiving chemo-immunotherapy.
Topics: Adult; Aged; Aminopyrine; Aminopyrine N-Demethylase; BCG Vaccine; Biotransformation; Breath Tests; Cyclophosphamide; Dacarbazine; Female; Humans; Immunotherapy; Liver; Male; Middle Aged; Mixed Function Oxygenases; Neoplasms; Propionibacterium acnes | 1978 |
[DTIC in the therapy of solid tumours (author's transl)].
Topics: Antineoplastic Agents; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Head and Neck Neoplasms; Humans; Melanoma; Neoplasm Metastasis; Neoplasms; Otorhinolaryngologic Diseases; Sarcoma, Kaposi; Soft Tissue Neoplasms; Thymoma; Thymus Neoplasms; Triazenes | 1978 |
Interrelationship between chemotherapy and immunotherapy in the treatment of disseminated disease.
Topics: Animals; Carmustine; Dacarbazine; Humans; Immunity; Immunotherapy; Leukemia L1210; Methotrexate; Mice; Mice, Inbred BALB C; Neoplasms | 1978 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neoplasms; Cyclophosphamide; Dacarbazine; Doxorubicin; Drug Evaluation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lomustine; Lung Neoplasms; Male; Melanoma; Mitolactol; Neoplasms; Osteosarcoma; Pancreatic Neoplasms; Rectal Neoplasms; Vincristine | 1976 |
[Imidazole-carboxamides in anticancer chemotherapy].
Topics: Amides; Animals; Dacarbazine; Drug Evaluation; Humans; Neoplasms | 1977 |
Severe myelosuppression from piperazinedione, (NSC No. 135758), cyclophosphamide plus dimethyl-triazeno-imidazole carboxamide (DTIC).
Topics: Bone Marrow; Cyclophosphamide; Dacarbazine; Drug Therapy, Combination; Humans; Neoplasms; Piperazines; Piperidines; Triazenes | 1977 |
Combination chemotherapy with adramycin (NSC-123127) and dimethyl triazeno imidazole carboxamide (DTIC) (NSC-45388) in children with metastatic solid tumors.
Topics: Child; Dacarbazine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Male; Neoplasm Metastasis; Neoplasms; Pneumonia; Remission, Spontaneous; Triazenes | 1976 |
Chemoimmunotherapy of human solid tumors.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Colonic Neoplasms; Dacarbazine; Drug Therapy, Combination; Humans; Immunization Schedule; Immunotherapy; Lung Neoplasms; Lymphatic Metastasis; Lymphoma; Melanoma; Neoplasms; Neoplasms, Experimental; Osteosarcoma | 1976 |
Letter: DTIC (NSC-45388) toxicity.
Topics: Dacarbazine; Drug Administration Schedule; Humans; Neoplasms; Triazenes | 1976 |
Measurement by 32P-postlabelling of 7-methylguanine levels in white blood cell DNA of healthy individuals and cancer patients treated with dacarbazine and procarbazine. Human data and method development for 7-alkylguanines.
Topics: Chromatography, Thin Layer; Dacarbazine; Deoxyguanine Nucleotides; DNA; DNA, Neoplasm; Guanine; Humans; Leukocytes; Neoplasms; Phosphorus Radioisotopes; Phosphorylation; Procarbazine | 1991 |
Sequential treatment of melanoma patients who progressed on interleukin-2 and dacarbazine by alpha-interferon and dacarbazine--a preliminary report.
Topics: Adult; Dacarbazine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Interferon Type I; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasms; Recombinant Proteins | 1990 |
Role of mathematical modeling in protocol formulation in cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Drug Resistance; Humans; Mechlorethamine; Models, Biological; Mutation; Neoplasms; Prednisone; Procarbazine; Vinblastine; Vincristine | 1985 |
Prodrugs in cancer chemotherapy.
Topics: Altretamine; Aniline Mustard; Animals; Antineoplastic Agents; Azo Compounds; Biotransformation; Chemistry, Pharmaceutical; Cyclophosphamide; Dacarbazine; Drug Evaluation; Female; Galactosidases; Glucuronosyltransferase; Humans; Imidazoles; Liver; Male; Nausea; Neoplasms; Neoplasms, Experimental; Structure-Activity Relationship; Temozolomide; Vomiting | 1986 |
Role of host responses in the drug treatment of metastasis.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Humans; Lung Neoplasms; Mice; Neoplasm Metastasis; Neoplasms; Triazenes | 1988 |
Heterogeneity of the response to inducers of differentiation and to cytostatics of tumor cell populations.
Topics: Antineoplastic Agents; Cell Differentiation; Cisplatin; Cytarabine; Dacarbazine; Dimethyl Sulfoxide; Dose-Response Relationship, Drug; Doxorubicin; Fluorouracil; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Promyelocytic, Acute; Melanoma; Neoplasms; Tetradecanoylphorbol Acetate; Tretinoin; Tumor Cells, Cultured | 1988 |
Cross-sensitivity of methylating agents, hydroxyurea, and methotrexate in human tumor cells of the Mer- phenotype.
Topics: Adenoviridae; Alkylating Agents; Cell Line; Cell Survival; Dacarbazine; Drug Resistance; Humans; Hydroxyurea; Methotrexate; Methyltransferases; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Virus Replication | 1986 |
[Research project of cancer chemotherapy].
Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Cisplatin; Dacarbazine; Etoposide; Humans; International Cooperation; Japan; Neoplasms; Research; Thioguanine; United States | 1985 |